Genprex Inc GNPX

NAS: GNPX | ISIN: US3724461047   14/05/2024
2,570 USD (+7,53%)
(+7,53%)   14/05/2024

14 mei 2024 · Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

13 mei 2024 · Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors · Persbericht

9 mei 2024 · Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner · Persbericht

1 mei 2024 · Genprex to Present and Participate at Upcoming May Investor and Industry Conferences · Persbericht

9 april 2024 · Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting · Persbericht

3 april 2024 · Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

2 april 2024 · Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System · Persbericht

22 maart 2024 · Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

19 maart 2024 · Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

19 maart 2024 · Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

12 maart 2024 · Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers · Persbericht

6 maart 2024 · Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting · Persbericht

7 februari 2024 · Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators · Persbericht

6 februari 2024 · Genprex to Present at Upcoming BIO CEO & Investor Conference · Persbericht

5 februari 2024 · Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer · Persbericht

31 januari 2024 · Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 · Persbericht

5 januari 2024 · Genprex Provides Business Update and Outlook for 2024 · Persbericht

1 november 2023 · Genprex to Present at BIO-Europe 2023 Conference · Persbericht

20 oktober 2023 · Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers" · Persbericht

4 oktober 2023 · Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics · Persbericht

Mijn selecties